Search clinical trials for: Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]

Total 34 results

Helwan University

Completed

Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

Chronic Hepatitis C

Egypt
The Third Affiliated Hospital of Guangzhou Medical...

Recruiting

The Efficacy of Vosevi in Treating DAA-experienced Patients

Chronic Hepatitis C | Medication Reaction

China
Partners in Health

Unknown

Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) (SHARED3)

Hepatitis C, Chronic

Rwanda
Peking University People's Hospital

Not yet recruiting

Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis

Hepatitis C | Cirrhosis
National Taiwan University Hospital

Recruiting

Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection

Hepatitis C Virus Infection | Treatment Side Effects | Effect of Drug | Adherence, Treatment

Taiwan
University of Maryland, Baltimore
Merck Sharp & Dohme LLC; National Institutes of Health (NIH)

Completed

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication (CHROME)

Cardiovascular Diseases | Hepatitis C | Hiv

United States
University of California, San Francisco

Completed

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant (PRO-ACT:)

Hepatitis C | Transplantation Disease Transmission

United States
Catherine Anne Chappell
Gilead Sciences

Recruiting

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (STORC)

Hepatitis C, Chronic | Pregnancy; Infection

United States, Canada
Johns Hopkins University

Completed

deLIVER: Direct Acting Antiviral Effects on the Liver (deLIVER)

HIV | Liver Disease | HCV Coinfection

United States
Ohio State University

Completed

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

Hepatitis C | HCV | Kidney Transplant

United States
Gilead Sciences

Terminated

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

Hepatitis C Virus Infection

United States, United Kingdom, Australia, Germany, Italy, New Zealand, Belgium, Poland, Russian Federation
University of Maryland, Baltimore
Gilead Sciences; Unity Health Care, Inc.

Completed

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience (RESOLVE)

Chronic Hepatitis C

United States
Radboud University Medical Center

Withdrawn

Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet (CRUSADE-1)

HCV

Netherlands, Germany
Hannover Medical School
Gilead Sciences; HepNet Study House, German Liverfoundation; German Center for...

Completed

Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

Hepatitis C | Acute Hepatitis C

Germany
National Taiwan University Hospital

Completed

eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs

Hepatitis C | Viral Hepatitis C | Renal Disease

Taiwan
Queen Mary University of London
University of Oxford; Aga Khan University; University of Bristol; Dow University...

Enrolling by invitation

Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan

Hepatitis C

Pakistan
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-1)

Hepatitis C

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen

Hepatitis C Virus Infection

United States
Ain Shams University
Cairo University

Recruiting

Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children

HCV

Egypt
Qing XIe
Gilead Sciences; Tigermed Consulting Co., Ltd

Recruiting

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C (C-DIAMOND)

Hepatitis C, Chronic

China
Oswaldo Cruz Foundation
Conselho Nacional de Desenvolvimento Científico e Tecnológico

Recruiting

Safety and Efficacy of Decentralized HCV Treatment vs Standard-of-Care in Rio de Janeiro (Brazil) (HCVPCL05/20)

Hepatitis C

Brazil
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor (POLARIS-4)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis (POLARIS-3)

Hepatitis C Virus Infection

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-2)

Hepatitis C

United States, France, United Kingdom, Germany, Canada, Australia, New Zealand, Puerto Rico
Kirby Institute

Recruiting

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs (TOPIC)

Hepatitis C | Liver Cirrhoses | Liver Inflammation

Australia
Gilead Sciences

Completed

Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Hepatitis C Virus Infection

Korea, Republic of
Zagazig University
Cairo University

Unknown

Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4

Hepatitis C
Mansoura University Children Hospital

Completed

Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children

Hepatitis C, Chronic

Egypt
University of Maryland, Baltimore
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection (APOSTLE)

Hepatitis B

United States
University Hospital, Akershus

Unknown

HCV Treatment in a Low-threshold Clinic (Prindsen)

Hepatitis C | Substance Use Disorders

Norway
Macfarlane Burnet Institute for Medical Research...
The University of Queensland; Cairns Hinterland Health Hospital and Health...

Completed

Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30%

Hepatitis C

Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

Liver Cancer

United States
University of Dundee

Completed

A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study (ADVANCE)

Hepatitis C

United Kingdom
Assiut University

Unknown

Effect Of DAAs For Treatment Of HCV On Normal Kidney

Antiviral Drug Adverse Reaction

3

Subscribe